Tigris Pharmaceuticals Funding Round

1/16/2007

Venture Equity

$16,000,000

Series B

The proceeds from the financing will be used primarily to advance the development of Tigris' clinical and pre-clinical product pipeline, including its lead compound, A-007, a topical gel for the treatment of cervical intra-epithelial neoplasia (CIN) resulting from the human papilloma virus (HPV). A-007 has completed enrollment of two registration trials in Mexico in patients with high grade CIN (CIN II and III) and is currently enrolling patients in a large Phase II clinical trial in the U.S. Tigris has also completed enrollment on a Phase I/II clinical trial in patients with anal neoplasia (ASIL). If successfully developed, A-007 represents a non-invasive alternative to the current standard of care, loop electrosurgical excision surgery (LEEP), and could complement prophylactic vaccines to reduce the incidence of cervical cancer.

Out of Business

Biopharmaceutical

3359 Woods Edge Circle 103
Bonita Springs, FL 34134
USA

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology, infectious diseases and other areas of unmet medical need. Tigris is currently conducting a Phase II clinical study for A-007, its topical treatment for pre-cancerous and cancerous anogenital lesions associated with HPV.